NL301139I2 - Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat - Google Patents

Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat

Info

Publication number
NL301139I2
NL301139I2 NL301139C NL301139C NL301139I2 NL 301139 I2 NL301139 I2 NL 301139I2 NL 301139 C NL301139 C NL 301139C NL 301139 C NL301139 C NL 301139C NL 301139 I2 NL301139 I2 NL 301139I2
Authority
NL
Netherlands
Prior art keywords
selumetinib
anhydrous
optionally
solvate form
hydrogen sulphate
Prior art date
Application number
NL301139C
Other languages
English (en)
Other versions
NL301139I1 (nl
Original Assignee
Array Biopharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218759&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301139(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc
Publication of NL301139I1 publication Critical patent/NL301139I1/nl
Publication of NL301139I2 publication Critical patent/NL301139I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
NL301139C 2005-12-21 2021-10-27 Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat NL301139I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75278105P 2005-12-21 2005-12-21
PCT/US2006/061895 WO2007076245A2 (en) 2005-12-21 2006-12-12 Novel hydrogen sulfate salt

Publications (2)

Publication Number Publication Date
NL301139I1 NL301139I1 (nl) 2021-11-03
NL301139I2 true NL301139I2 (nl) 2022-02-22

Family

ID=38218759

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301139C NL301139I2 (nl) 2005-12-21 2021-10-27 Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat

Country Status (31)

Country Link
US (4) US20100016393A1 (nl)
EP (1) EP1968948B1 (nl)
JP (1) JP5127723B2 (nl)
KR (1) KR101361460B1 (nl)
CN (2) CN101360718B (nl)
AR (1) AR058696A1 (nl)
AU (1) AU2006330759B2 (nl)
BR (1) BRPI0620091B1 (nl)
CA (1) CA2634149C (nl)
CY (1) CY1114303T1 (nl)
DK (1) DK1968948T3 (nl)
EC (1) ECSP088597A (nl)
ES (1) ES2421746T3 (nl)
FR (1) FR21C1051I2 (nl)
HK (1) HK1124043A1 (nl)
HR (1) HRP20130663T1 (nl)
HU (1) HUS2100046I1 (nl)
IL (1) IL192224A (nl)
LT (1) LTC1968948I2 (nl)
MX (1) MX2008008298A (nl)
MY (1) MY157733A (nl)
NL (1) NL301139I2 (nl)
NZ (1) NZ569792A (nl)
PL (1) PL1968948T3 (nl)
PT (1) PT1968948E (nl)
RS (1) RS52843B (nl)
SI (1) SI1968948T1 (nl)
TW (1) TWI405756B (nl)
UA (1) UA93531C2 (nl)
WO (1) WO2007076245A2 (nl)
ZA (1) ZA200805705B (nl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482932B1 (en) 2002-03-13 2009-11-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
JP2011506420A (ja) * 2007-12-12 2011-03-03 アストラゼネカ アクチボラグ Ｍｅｋ阻害剤及びオーロラキナーゼ阻害剤１８８を含んでなる組合せ
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
JP6180425B2 (ja) 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN109456272A (zh) 2012-10-19 2019-03-12 阵列生物制药公司 Mek抑制剂的制备和包含mek抑制剂的制剂
AP2015008696A0 (en) 2013-03-06 2015-08-31 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
KR20180058716A (ko) * 2015-10-06 2018-06-01 레드힐 바이오파마 엘티디 암을 치료하기 위한 병용 요법
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2019096112A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
RS64236B1 (sr) * 2018-10-31 2023-06-30 Servier Lab Nova so bcl-2 inhibitora, kristalni oblik iste, postupak za njenu pripremu i farmaceutske kompozicije koje je sadrže
US20220405506A1 (en) * 2021-06-22 2022-12-22 Intrinsic Innovation Llc Systems and methods for a vision guided end effector
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
PT923585E (pt) 1996-07-18 2002-08-30 Pfizer Inibidores a base de fosfinato de metaloproteases de matriz
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0950059T3 (da) 1997-01-06 2004-11-01 Pfizer Cycliske sulfonderivater
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
EP0966438A1 (en) 1997-02-07 1999-12-29 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482932B1 (en) * 2002-03-13 2009-11-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان

Also Published As

Publication number Publication date
EP1968948A2 (en) 2008-09-17
US9562017B2 (en) 2017-02-07
MY157733A (en) 2016-07-15
JP5127723B2 (ja) 2013-01-23
US20140221443A1 (en) 2014-08-07
EP1968948B1 (en) 2013-05-22
CA2634149C (en) 2013-08-13
AR058696A1 (es) 2008-02-20
CN101360718A (zh) 2009-02-04
PL1968948T3 (pl) 2013-10-31
WO2007076245A2 (en) 2007-07-05
JP2009521487A (ja) 2009-06-04
HUS2100046I1 (hu) 2021-11-29
SI1968948T1 (sl) 2013-08-30
FR21C1051I1 (fr) 2021-12-24
NL301139I1 (nl) 2021-11-03
ECSP088597A (es) 2008-08-29
TWI405756B (zh) 2013-08-21
HRP20130663T1 (en) 2013-08-31
PT1968948E (pt) 2013-07-25
US20160024018A1 (en) 2016-01-28
WO2007076245A3 (en) 2008-01-24
US9156795B2 (en) 2015-10-13
ES2421746T3 (es) 2013-09-05
ZA200805705B (en) 2012-09-26
MX2008008298A (es) 2008-09-24
LTPA2021530I1 (nl) 2021-12-27
AU2006330759A1 (en) 2007-07-05
EP1968948A4 (en) 2010-12-15
CN102329270A (zh) 2012-01-25
US20100016393A1 (en) 2010-01-21
US20120253049A1 (en) 2012-10-04
AU2006330759B2 (en) 2012-12-06
HK1124043A1 (en) 2009-07-03
CA2634149A1 (en) 2007-07-05
IL192224A0 (en) 2009-02-11
KR20080080200A (ko) 2008-09-02
TW200800915A (en) 2008-01-01
CY1114303T1 (el) 2016-08-31
IL192224A (en) 2014-08-31
FR21C1051I2 (fr) 2023-02-17
LTC1968948I2 (nl) 2023-07-10
RS52843B (en) 2013-12-31
KR101361460B1 (ko) 2014-02-10
DK1968948T3 (da) 2013-08-26
CN101360718B (zh) 2012-01-11
NZ569792A (en) 2011-01-28
BRPI0620091A2 (pt) 2011-11-01
UA93531C2 (en) 2011-02-25
BRPI0620091B1 (pt) 2024-04-30

Similar Documents

Publication Publication Date Title
NL301139I2 (nl) Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I2 (nl) crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300946I2 (nl) Brexpiprazole, desgewenst in de vorm van een zout
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
GB0721285D0 (en) Method for tomographic inversion by matrix transformation
IL184175A0 (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
DK1730327T3 (da) Dampelektrolyse
ITMI20052085A1 (it) Tutore ambidestro per polso provvisto di immobilizzatore del pollice
DE602005027222D1 (de) Schaumbare zusammensetzung
EP1956065A4 (en) THINNING / FOAM-EMPOWERING MEDIUM
EP1852499A4 (en) AGENT PROMOTING NEUROTISATION
FR2887451B1 (fr) Composition cosmetique anhydre pigmentee
SI1917254T1 (sl) Postopek izdelave amorolfina
BRPI0923835A2 (pt) Agente de formação de espuma
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
FI20051205A0 (fi) Jatkuvatoiminen retortti
DK1843989T3 (da) Skumgips
PL1956903T3 (pl) Zastosowanie produktu chłonnego zawierającego pentano-1,5-diol jako dezodorant
ZA200605597B (en) Compositions for use with skin
ITTO20050058A1 (it) Procedimento per la produzione di idrogeno
ITTN20050014A1 (it) Stallonatore manuale portatile
SE0501726L (sv) Förtjockare
ITVR20050029A1 (it) Procedimento per produrre poliuretano